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Abstract
The memory B-cell (MBC) ELISpot assay is the main technique used to measure antigen-specific MBCs as a readout of
humoral immune memory. This assay relies on the ability of MBCs to differentiate into antibody-secreting cells (ASC) upon
polyclonal stimulation. The total number of IgG+ ASCs generated by mitogen-stimulation is often used as a reference point;
alternatively antigen-specific MBCs are expressed as a frequency of post-culture peripheral blood mononuclear cells (PBMC)
as a surrogate for absolute frequencies. Therefore, it is important to know whether IgG+ B-cells are uniformly expanded
during the preceding mitogen-culture as a true reflection of MBC frequencies ex vivo. We systematically compared B-cell
phenotype and proportions before and after mitogen stimulation in cultures of 269 peripheral blood mononuclear cell
samples from 62 volunteers by flow cytometry and analyzed the number of resulting ASCs. Our data show that the number
of total IgG+ ASCs detected by ELISpot after mitogen stimulation correlates with the proportion of IgG+ MBCs ex vivo,
highlighting its general robustness for comparisons of study cohorts at group level. The expansion of total and IgG+ B-cells
during mitogen-stimulation, however, was not identical in all cultures, but influenced by size and composition of the ex vivo
B-cell compartment. The uncorrected readout of antigen-specific MBCs per million post-culture PBMCs therefore only
preserves the quality, but not the magnitude of differences in the ex vivo MBC response between groups or time points,
particularly when comparing samples where the B-cell compartment substantially differs between cohorts or over time.
Therefore, expressing antigen-specific cells per total IgG+ ASCs is currently the best measure to correct for mitogen-culture
effects. Additionally, baseline information on the size and composition of the ex vivo B-cell compartment should be supplied
to additionally inform about differences or changes in the size and composition of the ex vivo MBC compartment.
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Introduction
Humoral immunity is crucial to combat many infections and to
provide protection against re-infection and after vaccination.
Primarily, antibodies are used as readouts for humoral immunity
since they can be easily measured by enzyme-linked immunoab-
sorbance assay (ELISA). Long-term humoral immune memory is,
however, not only conveyed by antibody-producing long-lived
plasma cells, but also relies on the efficient acquisition and
maintenance of memory B-cells (MBCs), who upon antigen re-
encounter can rapidly develop into antibody secreting cells (ASCs)
to mount a strong secondary antibody response [1].
Circulating MBCs have low frequencies and are quiescent, i.e.
do not secrete antibody. Two main methods addressing these
challenges have been developed to quantify the magnitude of the
circulating MBC response: Direct ex vivo quantification can be
performed using flow cytometry upon labelling of MBCs with
fluorescently labelled monomeric or tetrameric antigens [2–4].
Alternatively, MBC-secreted antibodies can be quantified (by
Enzyme-linked ImmunoSpot assay (ELISpot) or ELISA) following
a pre-activation step using mitogens to differentiate MBCs into
ASCs [5]. This method is readily applicable to large numbers of
samples and antigens (provided sufficient cells are available from
each sample), without the need for fluorescent labelling, which can
be challenging for individual antigens [6]. It has thus become the
main readout used to measure antigen-specific MBCs in the
context of infections, vaccinations or allergy [6–12]. A necessary
underlying, but yet untested, assumption made when using the
MBC ELISpot to quantify antigen-specific responses is that MBCs
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are differentiated into ASCs at a fixed ratio [13]. Antigen-specific
MBC responses measured using this technique are either reported
as the number of ASC per million post-culture peripheral blood
mononuclear cells (PBMC), or as percentage of total ASCs.
Expressing antigen-specific cells as a proportion of ASC-differen-
tiated MBC corrects for variation in both total MBC precursor
frequencies and potential differences in expansion during mitogen
culture between donors. Reporting antigen-specific ASCs as per
million post-culture PBMCs is mostly used to get insights into the
absolute frequency of antigen-specific MBCs. This is done to also
take into account inter-individual variations in total MBC
frequencies particularly when comparing across age groups
[11,13] that differ not just in their antigen-experience but also
the size and composition of the (memory) B-cell compartment
[11,14]. This readout, however, does not correct for expansion
and potential skewing of the MBC compartment during mitogen
culture. It is therefore important to know (i) whether B-cells are
indeed consistently expanded during mitogen culture, (ii) which
factors influence this expansion, and (iii) whether the total number
of Ig-secreting cells generated truly reflects MBC frequencies ex
vivo. One study has addressed this last point for antigen-specific
MBCs [4], but the readout by ELISA did not allow comparisons of
ASCs following mitogen stimulation and ex vivo MBCs on the
single-cell level. A follow-up study demonstrated that the two
possible readouts after culture with mitogens, limiting dilution
ELISpot/ELISA and bulk culture ELISpot, correlated for two out
of the three antigens analyzed [6], supporting the use of the
cheaper and less time consuming bulk ELISpot. However, none of
these studies investigated the effect of mitogen culture on B-cell
expansion, which would have affected both post-culture read-outs
equally.
In this study, we therefore investigated both the consistency of
B-cell expansion during mitogen culture as well as the robustness
of this assay to detect total IgG+ ASCs that correspond to ex vivo
IgG+ MBC frequencies, by systematically comparing B-cell
phenotype and proportions before and after mitogen stimulation
in a large number of human PBMC cultures.
Materials and Methods
Peripheral blood mononuclear cells
To enable systemic analysis of B-cell expansion and ASC
generation in a large number of mitogen-stimulation cultures, we
took advantage of 269 individual PBMC samples that were
collected longitudinally from 62 healthy adult volunteers (age
range 18–32 years) enrolled in two clinical trials conducted at the
Radboud university medical center (Nijmegen, The Netherlands)
and the Leiden University Medical Centre (Leiden, The Nether-
lands) between March 2011 and April 2012. Both studies received
approval by the Central Committee for Research Involving
Human Subjects of The Netherlands (CCMO; NL34273.091.10
and NL33904.091.10) and volunteers enrolled in the studies
provided written informed consent. The study team complied with
the Declaration of Helsinki and Good Clinical Practice including
monitoring of data. The trials are registered at ClinicalTrials.gov,
number NCT01236612 and NCT01218893.
In Study A [15], volunteers received a prophylactic dose of
chloroquine for three months and bites from 3615 Plasmodium
falciparum (Pf )-infected mosquitoes (Chloroquine prophylaxis
and sporozoites, CPS), and were subjected to challenge with Pf-
infected red blood cells (n = 9) or infective mosquito bites (n = 5).
Ten volunteers received only chloroquine prophylaxis and then a
single Pf challenge either with Pf-infected red blood cells (n = 5) or
mosquito-bites (n = 5). In Study B [16] volunteers undergoing
chloroquine chemoprophylaxis were immunized with bites from
either three times 15 (n = 5), ten (n = 9) or five (n = 10) Pf-infected
mosquitoes, or not-immunized (n = 5). All immunized and control
subjects in this study were subjected to mosquito-bite challenge.
Sampling of citrate anti-coagulated peripheral blood for
immunological analysis was performed at different time points
using CPT vacutainers (Becton Dickinson). In Study A and B,
samples were available for each volunteer from D0 (pre-
immunization, before onset of chloroquine prophylaxis), day
before challenge (C21) and 35 days after challenge (C+35). In
Study B, additional samples were available from one month (28
days) after each of the three immunizations (for CPS-immunized
volunteers only) as well as 140 days after challenge (C+140).
Additionally, we included single samples from 9 healthy, Dutch
adult malaria-naı¨ve volunteers. At none of the blood collection
time points for this study was any of the volunteers infected with
Pf. PBMCs were isolated by density centrifugation. Following four
washes in phosphate buffered saline (PBS), PBMCs were
cryopreserved at 206106 cells/ml in ice-cold fetal calf serum
(FCS; Gibco)/10% DMSO (Merck) using Mr. Frosty freezing
containers (Nalgene). PBMC samples were stored in vapour phase
nitrogen.
Mitogen stimulation
Differentiation of MBCs into ASCs in was initiated in bulk
PBMC cultures based on a previously established protocol [5],
using a stimulation cocktail composed of pokeweed mitogen
(PWM), S. aureus Cowan I protein A (SAC) and CpG. IL-10 was
added to the stimulation mix since a previous study showed that
this enhanced the efficiency of MBC into ASC differentiation by
more than 9 fold [6]. Briefly, PBMCs were thawed for 30 sec in a
37uC water bath and cold RPMI medium was immediately added
drop wise. After washing, the cells were re-suspended in RPMI
containing 10% FCS, 100 U/ml penicillin/streptomycin,
100 mM HEPES, 50 mM 2-b-Mercaptoethanol and 2 mM L-
Glutamine (all Invitrogen) and counted. 16106 cells/ml were
added to 25 cm2 cell culture flasks (Greiner). Culture medium was
supplemented with 50 ng/ml PWM lectin derived from Phyto-
lacca americana (Sigma-Aldrich), 1:5000 Protein A from Staph-
ylococcus aureus, Cowan Strain (Sigma-Aldrich), 2.5 mg/ml ODN
2006 (Type B CpG nucleotide-human TLR9 ligand; InvivoGen
tlrl-2006) and 25 ng/ml recombinant human IL-10 (PeproTech)
and incubated at 37uC, 5% CO2 for 5 days.
Memory B-cell ELISpot
MultiScreen Filter PVDF Immobilon plates (MSIPS4510,
Millipore) were pre-wetted with 35% Ethanol, rinsed twice with
PBS and coated with 10 mg/ml monoclonal antibodies to human
IgG (clones MT91/145; Mabtech) diluted in phosphate buffered
saline (PBS). After overnight incubation at 4uC, plates were
washed (16 PBS/0.05% Tween 20 (Sigma-Aldrich, PBST), 36
PBS) and blocked with 1% bovine serum albumin (BSA; Sigma-
Aldrich) in RPMI for 2 h at 37uC. Cells were harvested from the
flasks, counted and seeded in quadruplicates at both 1200 and
4000 cells per well. Filter plates were incubated for 6 h at 37uC,
5% CO2 with minimized ambient vibration. After washing (46
PBS, 46 PBST), immobilized IgG was labeled using polyclonal
goat anti-human IgG (Fcc) alkaline phosphatase (1:1000 in PBST
containing 0.5% FCS; Mabtech) overnight at 4uC. Following
thorough washing (46PBST, 46PBS, 36distilled water), alkaline
phosphatase substrate BCIP/NBT (Mabtech) was added and the
filter plates were kept in the dark until fully developed. Developed
plates were rinsed with water, left to dry and stored protected from
light until reading using the CTL ImmunoSpot Reader (Cellular
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Technology Ltd.). The mean number of IgG+ ASCs in
quadruplicate wells was calculated per million PBMC and
averaged between the two cell concentrations. To check for assay
background some wells on every plate received only medium
instead of cells (no background detected) or 46105 cells were
added to wells coated with 5 mg/ml the irrelevant antigen Bovine
Serum Albumin (background: 0.33 spots/well).
Flow cytometry analysis
IgG+ B-cells and B-cell proportions were analyzed prior to (ex
vivo; stain 1; Figure S1) and after mitogen culture (stain 2;
Figure S2). B-cell subsets ex vivo were distinguished as described
previously [17]. For post-mitogen culture phenotyping we chose a
different staining panel for the following reasons: (i) mitogen
stimulation results in a down-regulation of CD19 expression,
necessitating the inclusion of CD20 to identify B-cells. (ii) we
aimed to assess proliferation after stimulation, thus including Ki67.
(iii) in previous experiments we found that CD21 as well as IgD
expression are down-regulated during culture of B-cells, while
CD38 expression is strongly up-regulated in the majority of B-cells
by mitogen-stimulation (Figure S3), thus preventing us to use the
same gating strategy to distinguish different B-cells subsets after 5
days of culture.
56105 to 16106 cells per stain were transferred to 96 wells V-
bottom plate (Sarstedt), washed with PBS and incubated for
30 min on ice with 50 ml viability dye diluted in PBS (fixable
viability dye eFluor 450, eBioscience (stain 1); aqua LIVE/DEAD
fixable dead cell stain, Invitrogen (stain 2)). Cells were washed
twice with staining buffer (PBS/0.5% BSA), and stained with 50 ml
antibody cocktail diluted in staining buffer for 30 min at room
temperature (RT). Antibodies used for surface staining are listed in
Table 1 and Table 2. After another wash, cells were re-
suspended in 50 ml fixation/permeabilization buffer (eBioscience),
incubated for 30 min at 4uC, and washed with 150 ml permea-
bilization buffer (eBioscience). For intracellular staining, cells were
incubated for 30 min at RT with 50 ml antibody cocktail (stain 2;
Ki67 AlexaFluor 647 (B56); BD Biosciences) diluted in permea-
bilization buffer (eBioscience). Cells were washed with permeabi-
lization buffer and re-suspended in 200 ml PBS/1% paraformal-
dehyde. 100,000 to 200,000 events per sample were acquired on a
Cyan ADP 9-colour flow cytometer (Dako/Beckman Coulter) and
analysis performed using FlowJo v9.2 software.
Statistical analysis
Data were analyzed using GraphPad Prism v5. B-cell propor-
tions ex vivo versus post-culture were compared by Wilcoxon
matched pairs signed rank test. Skewing of distributions was tested
by D’Agostino and Pearson omnibus normality test. Relationships
between B-cell proportions, expansion (fold change; calculated by
dividing for each sample the absolute number of total (or IgG+) B-
cells post mitogen-culture by the absolute number of total (or IgG+)
B-cells ex vivo) and ASCs were analyzed by non-parametric
Spearman correlation. Correlation coefficients listed are for PBMC
samples of the 62 volunteers at baseline, i.e. a time point when all of
them where malaria-naı¨ve and none of them was undergoing
chloroquine prophylaxis. Correlation coefficients obtained for
baseline samples only were comparable to those obtained when
analyzing all 269 cultures from all collected time points.
Results
Applying both flow cytometry and ELISpot, we conducted a
systematic large-scale analysis of 269 PBMC samples (derived from
62 donors sampled over 1–7 time points) before and after mitogen-
stimulation (Figure 1A). We firstly determined the ex vivo
composition of the B-cell compartment (for subset definitions see
Table 3 and Figure S1), and particularly of IgG+ MBCs, from
which IgG+ ASCs originate. Upon thawing of cryopreserved
PBMCs, B-cells made up 5.97% (median, interquartile range
(IQR) 4.26–8.25%) of PBMCs, and 7.86% (median; IQR 5.69–
11.5%) of these B-cells were IgG+. The IgG+ B-cell compartment
was largely composed of CD38lowIgD-CD102 MBCs
(Figure 1B), dominated by CD21+CD27+ classical MBCs
(cMBC; median 63.4%, IQR 55.9–67.8%), followed by CD21+
CD272 MBCs (median 20.3%, IQR 15.4–24.6%). Three other
MBC populations constituted 3.3–5% each of the IgG+ B-cell
compartment, i.e. CD212CD272 atypical MBCs (atypMBC),
CD212CD27+ activated MBC (actMBC) and IgD+CD21+
CD27+ non-switched MBCs (nsMBC). With the exception of a
slight dip in total B-cells four weeks after the last immunization,
both the size of the total and IgG+ circulating B-cell compartment,
and the proportions of the different MBC subsets remained
constant over time in the 53 donors from which multiple samples
were available (Table S1 and Table S2), highlighting that the
interventions the volunteers underwent in the clinical trials had no
biasing effect on the samples analyzed.
Recovery of total seeded PBMC after 5 days of culture in the
presence of mitogens was 95.45% (median, IQR 82.9–112.1%).
Consistent with 90.4% (median; IQR 87.5–92.1%) of B-cells
proliferating at day 5 (based on Ki67 staining, Figure S3),
mitogen-stimulation successfully increased the proportion of total
B-cells (Figure 1C, p,0.0001) and IgG+ B-cells within recovered
PBMCs in all cultures (Figure 1D, p,0.0001).
While the absolute number of both total and IgG+ B-cells prior
to culture correlated with their number after culture, this
relationship was stronger for total B-cells (Spearman r = 0.87,
p,0.0001; Figure 2A), than for IgG+ B-cells (r = 0.67, p,0.0001;
Figure 2B). For total B-cells, the median fold increase in absolute
numbers over 5 days of culture was 6.04 (IQR 5.0–7.74; p,
0.001), and this increase in total B-cell numbers during mitogen
culture was not normally distributed (D’Agostino and Pearson
omnibus normality test; skewness 1.06, kurtosis 2.04). Since all
mitogen cultures were performed under identical conditions, the
most likely confounding factor was the variation in the starting
proportion of total B-cells (median 5.97%, range 1.1–18.3%).
Indeed, we found that expansion of B-cells during mitogen culture
was variable and dependent of B-cell proportions before stimula-
tion with an inverse and non-linear (exponential decay) relation-
ship between the ex vivo proportion and the fold increase in both
their percentage (r =20.69, p,0.0001, data not shown) and
absolute number (r =20.38, p = 0.023; Figure 2C) during
culture. The largest expansion was found in cultures with the
lowest starting proportions of total B-cells.
We next addressed whether mitogen culture affected the
composition of the B-cell compartment. Overall, proportions of
IgG+ cells within the B-cell pool only increased slightly (pre- versus
post-culture: median with IQR 7.68% (5.7–11.5%) and 10.3%
(7.7–12.8%), respectively). However, as for B-cells within total
PBMCs, we also found that the ex vivo percentage of IgG+ cells
strongly influenced their expansion within the B-cell pool, with a
strong inverse and skewed correlation (Figure 2D, r =20.65, p,
0.0001) between their starting proportions and fold increase
during culture (median fold change post-culture/ex vivo 1.22, IQR
0.88–1.6; skewness 7.1; kurtosis 58.1). These effects of pre-culture
size and composition of the B-cell pool on the efficiency of
mitogen-driven expansion also affected the increase in IgG+ B-
cells, with a strong inverse correlation between starting propor-
tions and the increase in their percentage (r =20.76, p,0.0001,
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data not shown) or absolute numbers (r =20.70, p,0.0001;
Figure 2E): This was particularly evident in cultures with a low
proportion of starting IgG+ B-cells (,0.5% of PBMCs; 155/269),
where expansion was higher (median fold increase 9.3), more
variable (IQR 6.7–13.4) and skewed (skewness 5.6, kurtosis 34.7)
than in cultures with higher pre-culture proportions of IgG+ B-
cells ($0.5% of PBMC; 114/269; median fold increase 5.3; IQR
4.4–6.7; skewness 2.2, kurtosis 7.8). Finally, expansion of IgG+ B-
cells was higher than that of IgG2 B-cells (Figure 2E, F; median
fold increase 7.16 vs 5.86; p,0,0001), and expansion of IgG+ B-
cells more strongly influenced by their starting proportion
(skewness 6.9, kurtosis 55.9; Spearman r =20.70) than IgG2 B-
cells (skewness 0.99, kurtosis 1.7; Spearman r =20.29). Taken
together, differences in both size and composition of the ex vivo B-
cell compartment do directly influence the outcome of mitogen-
stimulation cultures.
When comparing the number of IgG+ B-cells determined by
flow cytometry to the number of IgG+ ACSs detected by ELISpot,
both per million PBMCs post-culture, we found that the number
of IgG+ B-cells, although in a similar range, was slightly but
significantly higher than that of IgG+ ASCs (Figure 3A;
p = 0.003). This suggests that the majority of IgG+ B-cells
expanded during mitogen culture also differentiate into ASCs.
There was, however, only a relatively weak correlation between
the proportion of IgG+ B-cells and IgG+ ASCs after mitogen
culture (Spearman r = 0.48, p,0.0001; Figure 3B), showing that
for a large number of cultures, staining of post-culture PBMCs for
surface IgG will overestimate the potential of these cells to secrete
IgG, as detected by ELISpot. When IgG+ ASC numbers (per
million PBMCs) were compared instead to the ex vivo proportion
of IgG+ cells within PBMCs prior to culture, this correlation
improved (r = 0.55, p,0.0001; Figure 3C), showing that IgG+
ASCs detected by MBC ELISpot are overall a good estimate of ex
vivo MBC frequencies. Moreover, when taking out variations in
the size of the B-cell pool by analyzing ex vivo IgG+ proportions
within the B-cell compartment, the correlation with IgG+ ASC
numbers post-mitogen culture improved further (r = 0.65, p,
0.0001; Figure 3D). This correlation was the same for IgG+
Table 1. Antibodies used for ex vivo flow cytometry analysis.
Purpose Target antigen Fluorochrome Clone Supplier
Viability fixable viability eFluor 450 n/a eBioscience
Dump channela CD3 FITC OKT3 Biolegend
CD56 FITC HCD56 Biolegend
CD14 FITC HCD14 Biolegend
B-cell lineage CD19 APC-eF780 HIB19 eBioscience
B-cell subset CD10 ECD ALB1 BeckmanCoulter
CD38 PerCp HIT2 Biolegend
CD27 PC7 IA4CD27 BeckmanCoulter
CD21 APC B-ly4 BD Biosciences
IgD biotin IA6-2 BD Biosciences
Streptavidin Pacific Orange n/a Invitrogen
BCR isotype IgG PE IS11-3B2.2.3 Miltenyi Biotech
aDump channel comprised of lineage markers to gate out non-relevant PBMC subsets.
n/a = not applicable.
BCR =B-cell receptor.
doi:10.1371/journal.pone.0102885.t001
Table 2. Antibodies used for post-culture flow cytometry analysis.
Purpose Target antigen Fluorochrome Clone Supplier
Viability lived/dead stain aqua n/a Invitrogen
Dump channela CD3 FITC OKT3 Biolegend
CD56 FITC HCD56 Biolegend
CD14 FITC HCD14 Biolegend
B-cell lineage CD19 APC-eF780 HIB19 eBioscience
CD20 Pacific Blue 2H7 Biolegend
B-cell activation CD38 PerCp HIT2 Biolegend
BCR isotype IgG PE IS11-3B2.2.3 Miltenyi Biotech
Proliferation Ki67 Alexa Fluor 647 B56 BD Biosciences
aDump channel comprised of lineage markers to gate out non-relevant PBMC subsets.
n/a = not applicable.
BCR =B-cell receptor.
doi:10.1371/journal.pone.0102885.t002
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Figure 1. Expansion of total and IgG+ B-cells following mitogen-stimulation. Panel (A) schematically illustrates the cellular composition of
PBMCs directly ex vivo and after mitogen culture. The grey circle represents total PBMCs, the blue circle all CD19+ B-cells and the orange triangle IgG+
B-cells. (B) The composition of the IgG+ B-cell compartment ex vivo was analyzed by flow cytometry and is depicted as median proportions of
individual B-cell subsets within total CD19+ B-cells for baseline samples of 62 donors. The individual B-cell subsets were subdivided based on IgD,
CD38, CD10, CD21 and CD27 expression and include five memory B-cell subsets: classical MBCs (cMBCs, red), CD272 MBCs (yellow), activated MBCs
(actMBC, black), atypical MBCs (atypMBC, green) and non-switched MBCs (nsMBC, white). Depicted in shades of grey are plasma blasts (PB), activated
naı¨ve B-cells (actN), classical naı¨ve B-cells (cN) and double-negative naı¨ve B-cells (dnN). Panels C–D show ex vivo and post-culture proportions of total
CD19+ B-cells (C, blue dots) and IgG+CD19+ B-cells (D, orange dots) within viable PBMCs. Black lines indicate the median. Dots show all 269 cultures.
doi:10.1371/journal.pone.0102885.g001
Table 3. Definition of B-cell subsets ex vivo.
B-cell subset Abbreviation IgD CD38 CD10 CD27 CD21
Classical MBCs cMBC 2 low 2 + +
CD272 MBCs CD272 MBC 2 low 2 2 +
Activated MBCs actMBC 2 low 2 + 2
Atypical MBCs atypMBC 2 low 2 2 2
Non-switched MBCs nsMBC + low 2 + +
Classical naı¨ve B-cells cN + low 2 2 +
Activate naı¨ve B-cells actN + low 2 + 2
Double-negative naı¨ve B-cells dnN + low 2 2 2
Transitional B-cells TBC + hi + 2 n/a
Plasma blasts PB 2 hi 2 + n/a
doi:10.1371/journal.pone.0102885.t003
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Figure 2. Size and composition of the B-cell compartment ex vivo influences B-cell expansion during culture. Flow cytometry analysis
was performed to determine proportions and subsequently calculate absolute numbers of (A) total CD19+ B-cells (blue dots) and (B) IgG+CD19+ B-
cells (orange dots) ex vivo and post-culture. Ex vivo proportions of (C) total CD19+ B-cells (blue dots) within viable PBMCs were plotted against the
fold change in their absolute numbers, and (D) IgG+ B-cells (orange dots) within total CD19+ B-cells were plotted against the fold change in their
proportion within the B-cell compartment. (E) Proportions of IgG+CD19+ B-cells (orange dots) and (F) IgG2CD19+ B-cells (green dots) within viable
PBMCs were plotted against the fold increase in their respective absolute numbers post-culture compared to ex vivo. Colored dots show cultures
from all 269 stimulated samples (3–7 time points per volunteer), while black dots show the cultures from only the 62 baseline samples (1 for each
individual volunteer). The black dashed line indicates the median fold change (with value), grey dotted lines represent the upper and lower limit of
the interquartile range. Spearman r and p values are shown for analysis of baseline samples (black dots) from the 62 donors assessed.
doi:10.1371/journal.pone.0102885.g002
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cMBCs, which constitute the largest proportion of the IgG+ B-cell
pool (r = 0.65, p,0.0001). IgG+ ASC numbers post-culture
further correlated with the ex vivo proportions of IgG+ CD272
MBCs (r = 0.51, p,0.0001), the second largest population within
IgG+ MBCs, but not for IgG+ atypMBCs (r = 0.24, p = 0.06). Of
note, across all baseline samples of 62 volunteers, the ratio of
atypMBCs/cMBCs correlated inversely with the proportion of
IgG+ cMBCs ex vivo (r =20.54, p,0.0001), but correlated
positively with the expansion of IgG+ B-cell numbers during
mitogen culture (r = 0.49, p,0.0001, data not shown).
Discussion
The MBC ELISpot assay is the most widely used method to
quantify MBC responses in addition to plasma antibodies as an
independent readout of humoral immune memory [6–12,18]. A
basic assumption when using the MBC ELISpot assay to estimate
the frequency of antigen-specific MBCs is that in the preceding
mitogen-culture, all MBCs are expanded and differentiate into
ASCs in a constant manner or at a fixed ratio, although this has
not been examined to date [13]. We show here that the expansion
of total and IgG+ B-cells during culture is not constant, but instead
influenced by both the size and composition of the ex vivo B-cell
compartment, which vary widely between individuals.
At group level, the number of IgG+ ASCs detected by ELISpot
after mitogen stimulation indeed reflects the proportion of IgG+
MBCs ex vivo, in particular for the two major populations of IgG+
MBCs, i.e. cMBCs and CD272 MBCs. This good correlation
between total input (ex vivo IgG+ MBC) and output (IgG+ ASC) is
in line with a previous small-scale study on TTX-specific MBCs
[4] and highlights the general robustness of this assay to compare
antigen-specific MBC frequencies on group level (e.g. between
different cohorts). This relationship was found across cultures from
62 volunteers with a wide range of ex vivo IgG+ MBC frequencies.
We also observed, however, that the expansion of both B-cells and
IgG+ B-cells during culture showed an inverse correlation with the
size and composition of the pre-culture B-cell compartment. This
was particularly evident for IgG+ MBCs. As a result, when total or
antigen-specific MBCs are expressed as a proportion of total post-
mitogen culture PBMCs to estimate their frequency, this
introduced bias into the readout, rather than allowing to take
into account inter-individual variations in total ex vivo MBC
frequencies [13].
The reason underlying this inverse relation between the ex vivo
proportion of total or IgG+ B-cells with their respective increase in
absolute numbers during culture remains unknown. One possibil-
ity is that the T-cell compartment is relatively larger in cultures
with lower B-cell proportions, and thus more T-cells available for
cytokine production upon PWM-stimulation, providing more
favorable expansion conditions than in cultures with higher B-
cell and lower T-cell numbers. This factor would influence total B-
cell expansion whenever mitogen-stimulation is performed in bulk
PBMC cultures. It does not, however, explain the skewing for
IgG+ B-cells within the B-cell compartment, since cultures with
the lowest total B-cell proportion where not those with the lowest
proportion of IgG+ B-cells within the B-cell compartment and vise
versa. Alternatively, assuming the same expansion efficiency in all
samples, IgG+ B cells in samples with a high starting proportion
might die in culture due to crowding, limited nutrients or toxin
build up, whereas IgG+ B cells in samples with a low starting
proportion can continue to proliferate and differentiate until the
end of the 5 day culture. While this again may be true for the B-
cell compartment as a whole, we consider it unlikely to be the sole
reasons for the strong inverse relationship between starting-
proportion and expansion of IgG+ B-cells: Firstly, the strong
skewing effect was also observed within the B-cell compartment for
IgG+ B-cells. Secondly, albeit 10 times more numerous, starting
proportion of IgG2 B-cells (containing mostly naı¨ve B-cells and a
few IgA+ or IgM+ MBCs) had only a very weak influence on their
expansion in culture. This suggests that other reasons underlie
these differences in expansion efficiency of IgG+ B-cells.
The skewing effect of B-cell frequency and composition
particularly affected cultures with a low proportion of ex vivo
IgG+ MBCs, which were expanded with a greater magnitude and
variation than those in culture with high starting proportions. One
potential explanation for this observation is that expansion of
IgG+ MBCs might also be enhanced by direct cell-cell contact of
IgG+ B-cells with PWM-activated T-cells (for instance via CD40-
CD40L [19]): when the IgG+ B-cell population is smaller to begin
with, the likelihood for direct cell-cell contact may be lower, and
interactions thus more random, than when IgG+ B-cells are more
frequent. In line with a greater variation in expansion, when ex
vivo IgG+ MBC proportions were plotted against post-culture
IgG+ ASCs, the spread was wider and the correlation coefficient
weaker for cultures with lower starting proportions of IgG+ MBCs
(less than 0.5% of starting PBMCs). Thus, special care should be
taken when comparing absolute IgG+ MBC numbers between
subjects particularly with low starting frequencies of IgG+ MBCs,
such as young children [11,14]. In such a case, expressing antigen-
specific MBCs as a proportion of post-culture PBMCs gives even
less insight into their actual ex vivo frequencies than when
comparing across samples with a wide range of starting IgG+
MBC proportions. Expressing antigen-specific IgG+ MBCs as a
proportion of IgG+ ASCs is therefore necessary to correct for this
great variation in expansion. Prior knowledge of the starting
concentration of IgG+ MBCs (e.g. by whole blood staining in a
small volume prior to cryopreservation) might provide valuable
additional information to accurately estimate differences in
antigen-specific IgG+ MBC precursor frequencies: This informa-
tion may be used to determine whether an actual difference in
IgG+ MBC frequencies or MBC subsets exists between two
groups, or whether they are comparable and differences in
antigen-specific cells per total ASCs thus also reflect a different
magnitude of the antigen-specific MBC response.
Another basic assumption of the MBC ELISpot assay is that all
antigen-specific cell subsets have an equal ability to differentiate
into ASCs. In our hands the number of post-culture surface IgG+
B-cells, however, did not fully predict the number of IgG+ ASCs.
One potential reason could be the down-regulation of surface IgG
expression on differentiating ASCs mitogen culture. This would
lead to an underestimation of IgG+ ASCs, which could be rectified
by performing intracellular IgG staining post culture. However,
after mitogen culture the number of surface IgG+ B-cells slightly
but significantly exceeds, and thus over- rather under-estimates the
number of IgG+ ASCs. While we can further not formally show
that all expanded IgG+ B-cells are indeed plasma blasts (since
staining for CD27 was not performed in addition to CD38), we
find that the number of post-culture IgG+ cells and IgG+ ASCs
correlates (Spearman r = 0.48, p,0.0001), indicating that at least a
major proportion of those cell populations does overlap. More-
over, these data indicate that not all IgG+ B-cells (ex vivo and post
culture) actually acquire ASC function, as previously shown at the
single cell level for isotype-switched MBCs after stimulation with
CpG and cytokines [20,21]. A marker identifying MBC subsets
with the capacity to become ASCs is unfortunately still lacking
[20], and this may further differ depending on the combination of
stimuli chosen: Since the description of the MBC ELISpot by
Crotty et al. [5], many different polyclonal stimulation protocols
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relying on the activation of Toll-like receptors as well as cytokine
receptor signaling have been tested to effectively differentiate
MBCs into ASCs. Here we choose a stimulation cocktail
containing PWM, SAC, CpG and IL-10, which was previously
shown to be the most efficient out of 12 different stimulation
protocols tested [6]. Based on the data we provide, future studies
using other effective stimulation protocols (e.g. IL-2 and R848
[9,10], or IL-15 and CpG [7]) or purified B-cells [18] should
determine whether the size and composition of the ex vivo B-cell
pool influences the expansion of total and IgG+ B cells during
culture.
Most IgG+ B-cells ex vivo are cMBCs, and their proportion
correlated as strongly with IgG+ ASCs detected by ELISpot as the
proportion of total ex vivo IgG+ B-cells. Curiously, low
proportions of IgG+ cMBCs within the B-cell compartment ex
vivo (and thus low numbers of IgG+ ASCs after mitogen culture)
were predominantly found in volunteers with high ex vivo ratios of
atypMBC to cMBC. This was particularly evident for one
volunteer, who at all three time points, at which PBMCs were
sampled, showed the highest number of IgG+ B-cells after mitogen
stimulation but only very low IgG+ ASC numbers, suggesting that
only a small fraction of the efficiently expanded IgG+ B-cells
actually secreted IgG: this volunteer had a very low proportion of
cMBCs and CD272MBCs within IgG+ B-cells, but a particularly
large proportion of atypMBCs prior to mitogen culture. This
observation would be consistent with previous studies that
reported atypMBCs from HIV-infected individuals to be less
efficient in differentiating into IgG+ ASCs in vitro, and similar
data are available for a very limited number of atypMBCs from
malaria-exposed subjects [12,22]. On the other hand, there is
evidence that atypMBCs from malaria-exposed individuals may
contribute to antibody production, since as for cMBCs, their BCR
sequences can be matched to circulating plasma antibodies [23].
Additionally, bulk-sorted atypMBCs in this study contained both
the membrane-bound and secreted form of IgG, however, a
contamination of this population with non-atypMBC antibody-
secreting cells cannot be fully excluded, since CD38hi cells were
not depleted [23]. It therefore remains to be conclusively
established whether atypMBCs indeed actively secrete antibodies
in vivo, or simply differentiate into ASCs like cMBCs (just
potentially less efficiently) and then contribute to IgG-secretion
upon antigenic stimulation. The extent to which atypMBCs and
cMBCs in both malaria-exposed and healthy, malaria-naı¨ve
individuals vary in their ability to differentiate into ASCs to
different stimuli also remains to be established. Should this indeed
be the case, then data not only on the size, but also the detailed
composition of the ex vivo IgG+ MBC pool might be helpful for
data interpretation, especially when comparing populations with a
broad range of proportions of atypMBC, such as individuals of
different age groups in malaria-endemic areas or in different
transmission settings [11,22].
Antigen-specific ASCs are often reported per million post-
culture PBMCs to get insights into the frequency of circulating
antigen-specific MBCs. This readout, however, does not correct
for differential expansion and thus skewing of the MBC
compartment during mitogen culture. Therefore only qualitative
(higher or lower ex vivo frequencies of antigen-specific cells) but
not quantitative differences between groups (which one aims to
examine when using this readout) are preserved. This is specifically
relevant for comparing antigen-specific MBCs between groups
that markedly differ in size and composition of the B-cell
compartment, such as between different age groups [11,14]. A
correction factor to accurately quantify antigen-specific MBC
responses (taking into account both the size of the B-cell
compartment and the proportion of IgG+ MBCs ex vivo), would
simplify analysis, but its determination is complicated by two main
aspects: (i) different IgG+ MBC subsets may have varying abilities
to differentiate into ASCs and (ii) other stimulation protocols may
introduce different degrees of skewing during culture, for instance
since receptor expression varies between MBC subsets [24]. In the
absence of such a correction factor, we conclude that it is not
possible to accurately estimate MBC frequencies by MBC
ELISpot on an individual level. For this question, limiting dilution
assay or ex vivo staining with fluorescently-labeled antigens [3,4]
or B-cell tetramers [2] remain the methods of choice.
An immediate practical implication of our finding is thus the
way that results from bulk-culture MBC ELISpot should be
reported: Specifically, we recommend not to express antigen-
specific MBCs as a proportion of post-culture PBMCs in an
attempt to compare their frequencies - particularly between clearly
different cohorts, since this actually introduces bias. Instead, to
allow interpretation of MBC ELISpot data in a meaningful
manner, we propose to always include total IgG+ ASCs as a
reference point to correct for variations in MBC precursor
frequencies and hence expansion during mitogen culture between
donors. Between relatively homogenous groups (in regards to their
B-cell compartment), expressing antigen-specific cells per total
ASCs is currently the best measure to correct for mitogen-culture
effects. The same is true for longitudinal studies where the size and
composition of the (memory) B-cell compartment does not alter
over time (as in the samples analyzed herein). In settings, however,
where groups differ in the size and makeup of their (IgG+
memory) B-cell compartment (or these parameters alter over time
in longitudinal studies) due to age or pathogen exposure, we
propose that this information about the B-cell compartment
should be additionally provided as a separate measure. This will
also inform the reader appropriately whether it is simply the size of
the MBC compartment that differs between (age) groups or alters
over time, or the proportion of antigen-specific cells within the
MBC compartment, or both – information that is lost when only
providing the mitogen-culture biased readout of antigen-specific
MBCs per post-culture PBMCs.
Conclusions
The number of total IgG+ ASCs detected by ELISpot after
mitogen stimulation correlates with the proportion of IgG+ MBCs
ex vivo, highlighting the general robustness of this assay to
compare MBC responses between different cohorts, i.e. at group
level. The expansion of total and IgG+ B-cells during mitogen-
stimulation, however, was not identical in all cultures, but
influenced by both the size and composition of the ex vivo B-cell
compartment, which vary widely between individuals. The
Figure 3. Relationship between post-culture IgG+ ASC numbers and ex vivo or post-culture IgG+ B-cell proportions. After 5 days of
mitogen culture, proportions of IgG+ B-cells were analyzed by flow cytometry (orange dots) and IgG+ ASCs were quantified by ELISpot (red dots) and
expressed as per million post-culture PBMCs (A). Black lines indicate the median. Post-culture (B) and ex vivo proportions (C) of IgG+ cells within
PBMCs, and ex vivo proportions of IgG+ cells within CD19+ B-cells (D) were plotted against the number of IgG+ ASCs per million PBMCs. Light red
dots show cultures from all 269 stimulated samples (3–7 time points per volunteer), while black dots show the cultures from only the 62 baseline
samples (1 for each individual volunteer).
doi:10.1371/journal.pone.0102885.g003
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uncorrected readout of antigen-specific MBCs per million post-
culture PBMCs therefore only preserves the quality, but not the
quantity of differences in the ex vivo MBC response between
samples and thus groups or time points. Expressing antigen-
specific cells per IgG+ ASCs is currently the best measure to
correct for differences in the ex vivo B-cell compartment and
resulting mitogen-culture effects. To be able to evaluate not only
changes within the MBC compartment, but their actual magni-
tude within the circulation, additional information on the size and
composition of the ex vivo B-cell compartment should be supplied
as a separate measure, particularly under circumstances when the
proportions IgG+ MBC are highly variable or proportions of B-
cell subsets are altered by environmental factors either between
groups or over time.
Supporting Information
Figure S1 Gating strategy of total and IgG+ B-cells ex
vivo. (A) CD19+ B-cell were identified following exclusion of
debris, doublets, dead cells and CD3/CD56/CD14-positive cells.
(B) shows gating for IgG+ B-cells. This IgG+ gate was later applied
to individual B-cell subsets, which were gates as follows: (C)
CD19+ B-cells were first subdivided based on IgD and CD38
expression. (D) CD10+ cells were excluded from all B-cell
populations except IgD+CD38hi B-cells, which were specifically
subgated based on CD10 expression. (E) CD38hi B-cells were
divided into CD102IgD2CD38hiCD27+ plasma blasts (PB, i)
and CD10+ IgD+CD38hiCD272 transitional B-cells (TBC, ii).
CD38lowCD102 B-cells were subdivided into four pairs of
switched/memory (IgD2) and non-switched/naı¨ve (IgD+) B-cell
populations: CD212CD27+ activated MBCs (actMBC, iii) and
activated naı¨ve B-cells (actN, iv); CD21+CD27+ classical MBCs
(cMBC, v) and non-switched MBCs (nsMBC, vi); CD21+CD272
MBC (CD272 MBC, vii) and classical naı¨ve B-cells (cN, viii); and
CD212CD272 atypical MBCs (atypMBC, ix) and double-
negative naı¨ve B-cells (dnN, x). (F) shows the proportions of the
ten B-cell subsets of the total ex vivo B-cell pool and (G) the
proportion of IgG+ cells within each individual B-cell subset for
the baseline samples of all 62 volunteers.
(TIF)
Figure S2 Gating strategy of total and IgG+ B-cells after
5 day mitogen culture. Following (A) exclusion of debris,
doublets and dead cells, B-cells were identified by (B) firstly gating
on CD19+CD20+ cells and subsequently gating out CD3/CD56/
CD14-positive cells (Boolean gating). (C) shows gating for IgG+ B-
cells for two donors.
(TIF)
Figure S3 CD38 and Ki67 expression on B-cells after 5
day mitogen culture. (A) Ki67 and CD38 gates were based on
negative populations in total post-culture PBMCs (after exclusion
of debris, doublets and dead cells). (B) shows Ki67 and CD38
staining on post-culture B-cells. (C) Grey dots show the percentage
of Ki67 and CD38 positive cells within post-culture B-cells cultures
in all 269 stimulated samples, black lines indicate the median and
error bars the interquartile range.
(TIF)
Table S1 B-cells, IgG+ B-cells and MBC subsets in Study A ex
vivo samples over time. B-cell proportions and MBC subsets in
PBMC samples from Study A volunteers (n = 14 CPS-immunized
volunteers and n = 10 controls) were analyzed by flow cytometry.
CD19+ B-cell were identified following exclusion of debris,
doublets, dead cells and CD3/CD56/CD14-positive. Five MBC
populations were identified in the CD38lowCD102 B-cells
compartment as followed: IgD2CD21+CD27+ classical MBCs
(cMBC), IgD2CD21+CD272 MBC (CD272 MBC), IgD2
CD212CD27+ activated MBCs (actMBC), IgD2CD212
CD272 atypical MBCs (atypMBC) and IgD+CD21+CD27+
non-switched MBCs (nsMBC).
(DOC)
Table S2 B-cells, IgG+ B-cells and MBC subsets in Study B ex
vivo samples over time. B-cell proportions and MBC subsets in
PBMC samples from Study B volunteers (n = 24 CPS-immunized
volunteers and n = 5 controls) were analyzed by flow cytometry.
CD19+ B-cell were identified following exclusion of debris,
doublets, dead cells and CD3/CD56/CD14-positive. Five MBC
populations were identified in the CD38lowCD102 B-cells
compartment as followed: IgD2CD21+CD27+ classical MBCs
(cMBC), IgD2CD21+CD272 MBC (CD272 MBC), IgD2
CD212CD27+ activated MBCs (actMBC), IgD2CD212
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